Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase I Study of ATG-031 in Patients With Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

NCT06028373 is registered in ClinicalTrials.gov with Antengene Biologics Limited as lead sponsor.

NCT NCT06028373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06028373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase I Study of ATG-031 in Patients With Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Lead sponsor
Antengene Biologics Limited
Phase
Phase 1
Overall status
Terminated
Start date
December 8, 2023
Completion date
June 12, 2026
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, b-cell non-hodgkin lymphomas